NASDAQ:ACLX

Arcellx Stock Insider Trading

Healthcare > Biotechnology

Buy ACLX

*Your capital is at risk

$115.07

+0 (+0%)

At Close: Jun 03, 2026

Arcellx Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -63.73. In total, the insiders bought 1.66M and sold 6.21M ACLX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-63.73
● Buy	1.66M shares
● Sell	6.21M shares
32% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Apr 28, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -63.73. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 28, 2026 Sell	Common Stock U-Tender	Behbahani Ali Director	Director	2 706 Value: $311.2K
Apr 28, 2026 Sell	Common Stock U-Tender	Carroll Jill Director	Director	1 479 148 Value: $0.17B
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Carroll Jill Director	Director	11 459 Value: $434.8K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Carroll Jill Director	Director	8 011 Value: $411.0K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Carroll Jill Director	Director	9 174 Value: $584.2K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Ware Olivia C Director	Director	36 806 Value: $280.1K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Ware Olivia C Director	Director	11 459 Value: $434.8K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Ware Olivia C Director	Director	8 011 Value: $411.0K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Ware Olivia C Director	Director	9 174 Value: $584.2K
Apr 28, 2026 Sell	Common Stock U-Tender	Lubner David Charles Director	Director	21 659 Value: $2.49M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Lubner David Charles Director	Director	13 626 Value: $93.1K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Lubner David Charles Director	Director	59 405 Value: $373.1K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Lubner David Charles Director	Director	31 794 Value: $211.7K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Lubner David Charles Director	Director	61 538 Value: $923.1K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Lubner David Charles Director	Director	11 459 Value: $434.8K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Lubner David Charles Director	Director	8 011 Value: $411.0K
Apr 28, 2026 Sell	Common Stock U-Tender	Galligan Andrew H Director	Director	5 000 Value: $575.0K
Apr 28, 2026 Buy	Performance-based Restricted Stock Unit A-Award	Gilson Michelle Chief Financial Officer	C-Suite Officer	59 028 Value: $6.79M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Gilson Michelle Chief Financial Officer	C-Suite Officer	70 796 Value: $2.20M
Apr 28, 2026 Sell	Performance-based Restricted Stock Unit D-Return	Gilson Michelle Chief Financial Officer	C-Suite Officer	59 028 Value: $0
Apr 28, 2026 Sell	Common Stock U-Tender	Gilson Michelle Chief Financial Officer	C-Suite Officer	5 000 Value: $575.0K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Gilson Michelle Chief Financial Officer	C-Suite Officer	32 500 Value: $649.0K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Heery Christopher Chief Medical Officer	Officer	132 416 Value: $1.99M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Heery Christopher Chief Medical Officer	Officer	40 000 Value: $798.8K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Heery Christopher Chief Medical Officer	Officer	60 096 Value: $3.37M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARCELLX, INC.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent Sp...

Read Full Profile Here